TGTX Tg Therapeutics Inc

Price (delayed)

$7.52

Market cap

$1.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.45

Enterprise value

$976.78M

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active ...

Highlights
Tg Therapeutics's gross profit has increased by 19% QoQ
The revenue rose by 18% QoQ
The company's net income rose by 6% QoQ but it fell by 2.4% YoY
TGTX's debt has soared by 92% YoY
The equity has dropped by 62% year-on-year and by 28% since the previous quarter

Key stats

What are the main financial stats of TGTX
Market
Shares outstanding
144.44M
Market cap
$1.09B
Enterprise value
$976.78M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.3
Price to sales (P/S)
127.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
123.46
Earnings
Revenue
$7.91M
EBIT
-$320.08M
EBITDA
-$319.78M
Free cash flow
-$283.31M
Per share
EPS
-$2.45
Free cash flow per share
-$2.11
Book value per share
$1.19
Revenue per share
$0.06
TBVPS
$2.25
Balance sheet
Total assets
$303.03M
Total liabilities
$132.64M
Debt
$77.57M
Equity
$170.39M
Working capital
$187.56M
Liquidity
Debt to equity
0.46
Current ratio
4.43
Quick ratio
4.31
Net debt/EBITDA
0.34
Margins
EBITDA margin
-4,041.7%
Gross margin
88.8%
Net margin
-4,126.5%
Operating margin
-4,075.3%
Efficiency
Return on assets
-83%
Return on equity
-118.5%
Return on invested capital
-470.7%
Return on capital employed
-128.9%
Return on sales
-4,045.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
20.71%
1 week
35.74%
1 month
33.57%
1 year
-68.03%
YTD
-60.42%
QTD
76.94%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$7.91M
Gross profit
$7.03M
Operating income
-$322.44M
Net income
-$326.49M
Gross margin
88.8%
Net margin
-4,126.5%
Tg Therapeutics's operating margin has surged by 88% YoY and by 21% QoQ
TGTX's net margin has soared by 88% YoY and by 21% QoQ
Tg Therapeutics's gross profit has increased by 19% QoQ
The revenue rose by 18% QoQ

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
P/E
N/A
P/B
6.3
P/S
127.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
123.46
Tg Therapeutics's EPS has increased by 7% QoQ and by 6% YoY
The P/B is 70% below the 5-year quarterly average of 17.3 and 58% below the last 4 quarters average of 12.3
The equity has dropped by 62% year-on-year and by 28% since the previous quarter
The P/S is 99% below the 5-year quarterly average of 7248.4 and 88% below the last 4 quarters average of 914.8
The revenue rose by 18% QoQ

Efficiency

How efficient is Tg Therapeutics business performance
TGTX's ROIC has soared by 89% YoY and by 46% QoQ
Tg Therapeutics's return on sales has surged by 88% YoY and by 21% QoQ
The company's return on equity fell by 24% YoY and by 17% QoQ
The ROA has contracted by 13% YoY and by 8% from the previous quarter

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The total assets is 128% higher than the total liabilities
The total assets fell by 45% YoY and by 20% QoQ
Tg Therapeutics's total liabilities has increased by 28% YoY but it has decreased by 7% QoQ
TGTX's debt is 54% lower than its equity
TGTX's debt has soared by 92% YoY
The equity has dropped by 62% year-on-year and by 28% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.